Promising Pipeline | Explore Corbus Pharmaceuticals' diverse portfolio, featuring potential best-in-class therapies for cancer and obesity, positioning the company for significant market impact |
Financial Fortitude | Delve into Corbus's robust financial position, with $120.1 million in cash reserves providing runway for key development milestones and future growth |
Market Opportunity | Learn how Corbus targets lucrative markets in oncology and obesity, with analysts projecting billion-dollar sales potential for lead candidates |
Analyst Outlook | Discover the bullish sentiment among analysts, with price targets ranging from $77 to $85, reflecting confidence in Corbus's innovative approach and market potential |
Metrics to compare | CRBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −1.6x | −0.3x | |
PEG Ratio | 0.06 | −0.01 | 0.00 | |
Price/Book | 1.6x | 4.6x | 2.6x | |
Price / LTM Sales | - | 7.0x | 3.0x | |
Upside (Analyst Target) | 312.6% | 81.0% | 53.8% | |
Fair Value Upside | Unlock | 3.2% | 8.6% | Unlock |
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.